Gene therapies for mucopolysaccharidoses
Open Access
- 29 May 2023
- journal article
- review article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 47 (1) , 135-144
Abstract
Current specific treatments for mucopolysaccharidoses (MPSs) include enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT). Both treatments are hampered by several limitations, including lack of efficacy on brain and skeletal manifestations, need for lifelong injections, and high costs. Therefore, more effective treatments are needed. Gene therapy in MPSs is aimed at obtaining high levels of the therapeutic enzyme in multiple tissues either by engrafted gene‐modified hematopoietic stem progenitor cells (ex vivo) or by direct infusion of a viral vector expressing the therapeutic gene (in vivo). This review focuses on the most recent clinical progress in gene therapies for MPSs. The various gene therapy approaches with their strengths and limitations are discussed.Keywords
This publication has 82 references indexed in Scilit:
- A highly secreted sulphamidase engineered to cross the blood‐brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIAEMBO Molecular Medicine, 2013
- Gene Therapy for Mucopolysaccharidosis Type VI Is Effective in Cats Without Pre-Existing Immunity to AAV8Human Gene Therapy, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid ProteinsMolecular Therapy, 2011
- Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene TransferMolecular Therapy, 2011
- Efficacy of Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2010
- Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapyBlood, 2009
- Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patientsJournal of Clinical Investigation, 2008
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1Journal of Clinical Investigation, 2008
- Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatmentNature Biotechnology, 2008